Pritumumab, the first therapeutic antibody for glioma patients.

Immunotherapy is now at the forefront of cancer therapeutic development. Gliomas are a particularly aggressive form of brain cancer for which immunotherapy may hold promise. Pritumumab (also known in the literature as CLNH11, CLN-IgG, and ACA-11) was the first monoclonal antibody tested in cancer patients. Pritumumab is a natural human monoclonal antibody developed from a B lymphocyte isolated from a regional draining lymph node of a patient with cervical carcinoma. The antibody binds ecto-domain vimentin on the surface of cancer cells. Pritumumab was originally tested in clinical trials with brain cancer patients in Japan where it demonstrated therapeutic benefit. It was reported to be a safe and effective therapy for brain cancer patients at doses 5-10 fold less than currently approved antibodies. Phase I dose escalation clinical trials are now being planned with pritumumab for the near future. Here we review data on the development and characterization of pritumumab, and review clinical trails data assessing immunotherapeutic effects of pritumumab for glioma patients.

[1]  M. Glassy,et al.  Abstract 2658: GPEx® system to increase production of pritumumab in a CHO cell line , 2014 .

[2]  S. Dübel,et al.  Handbook of Therapeutic Antibodies: Dübel/Handbook of Therapeutic Antibodies , 2014 .

[3]  J. Baselga,et al.  Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. , 2014, The Lancet. Oncology.

[4]  Mark C Glassy,et al.  Technical and ethical limitations in making human monoclonal antibodies (an overview). , 2014, Methods in molecular biology.

[5]  F. Marincola,et al.  Intravenous immunoglobulin-based immunotherapy: an arsenal of possibilities for patients and science. , 2009, Immunotherapy.

[6]  M. Glassy,et al.  Summary analysis of the pre-clinical and clinical results of brain tumor patients treated with pritumumab. , 2009, Human antibodies.

[7]  Santosh Kesari,et al.  Malignant gliomas in adults. , 2008, The New England journal of medicine.

[8]  E. Glassy,et al.  Cocktails of human anti-cancer antibodies show a synergistic effect in nude mouse tumor xenografts. , 2008, Human antibodies.

[9]  Johanna Ivaska,et al.  Novel functions of vimentin in cell adhesion, migration, and signaling. , 2007, Experimental cell research.

[10]  R. E. Peters,et al.  Growth of human-human hybridomas in serum-free media enhances antibody secretion , 1987, In Vitro Cellular & Developmental Biology.

[11]  M. Glassy,et al.  Requirements for human antibody cocktails for oncology , 2005, Expert opinion on biological therapy.

[12]  T. Kokunai.  [Anti-TA226 human monoclonal antibody (ACA-11) against glioma]. , 2002, Nihon rinsho. Japanese journal of clinical medicine.

[13]  Y. Yamamoto,et al.  Determination of the antigen/epitope that is recognized by human monoclonal antibody CLN-IgG. , 2001, Human antibodies.

[14]  Tanaka Takayuki,et al.  Results of an Immunotherapy using Human Monoclonal Antibody for Gliomas: Findings in Ten Cases. , 1996 .

[15]  Y. Aotsuka,et al.  Structural Analysis of Anti-cancer Antibody, CLN-IgG, and Anti-Idiotypic Antibody, Idio-No. 3, for the Study of Idiotope Image Transmission: An Insight into Antigen-Specific Human Monoclonal Antibody Therapy , 1996 .

[16]  Kunihiko Watanabe,et al.  Clinical Effect of CLN-IgG on Glioma and Its Correlation with the Induction of Antianti-Idiotypic Antibody in the Serum , 1996 .

[17]  H. Hagiwara,et al.  Generation of somatic cell hybrids capable of proliferating and secreting human monoclonal antibody without any growth factor supplements. , 1993, Human antibodies and hybridomas.

[18]  R. Ohno,et al.  Antibody dependent cell mediated cytotoxicity on human cervical carcinoma cell line, ME-180, with human monoclonal antibody. , 1992, Cancer letters.

[19]  S. Matsumoto,et al.  Antitumor Effects of Human Monoclonal Antibodies on Human Malignant Glioma Xenografts and Their Clinical Application , 1991 .

[20]  K. Ichikawa,et al.  Clinical Application of Radiolabeled Human X Human Monoclonal Antibody with Interferon in the Treatment of Malignant Glioma—Preliminary Report , 1991 .

[21]  H. Hagiwara,et al.  Preferential generation of IgG-producing human hybridomas against human tumor cells. , 1990, Journal of immunological methods.

[22]  T. Kokunai,et al.  Antigen related to cell proliferation in malignant gliomas recognized by a human monoclonal antibody. , 1990, Journal of neurosurgery.

[23]  Y. Aotsuka,et al.  Identification of a malignant cell associated antigen recognized by a human monoclonal antibody. , 1988, European journal of cancer & clinical oncology.

[24]  M. Glassy.  Immortalization of human lymphocytes from a tumor-involved lymph node. , 1987, Cancer research.

[25]  H. Hagiwara,et al.  Cytotoxicity of Mixed Human Monoclonal Antibodies Reacting to Tumor Antigens , 1987, Acta paediatrica Japonica : Overseas edition.

[26]  I. Royston,et al.  UC 729-6, a human lymphoblastoid B-cell line useful for generating antibody-secreting human-human hybridomas. , 1983, Proceedings of the National Academy of Sciences of the United States of America.